Performance of Lipoarabinomannan Assay using Cerebrospinal fluid for the diagnosis of Tuberculous meningitis among HIV patients. by Kwizera, Richard et al.
LSHTM Research Online
Kwizera, Richard; Cresswell, Fiona V; Mugumya, Gerald; Okirwoth, Micheal; Kagimu, Enock;
Bangdiwala, Ananta S; Williams, Darlisha A; Rhein, Joshua; Boulware, David R; Meya, David
B; (2019) Performance of Lipoarabinomannan Assay using Cerebrospinal fluid for the diagnosis





Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.






   Performance of Lipoarabinomannan Assay using
Cerebrospinal fluid for the diagnosis of Tuberculous meningitis
 among HIV patients [version 2; peer review: 2 approved]
Richard Kwizera ,     Fiona V. Cresswell , Gerald Mugumya ,
     Micheal Okirwoth , Enock Kagimu , Ananta S. Bangdiwala ,
























































 19 Aug 2019,  :123 (First published: 4
)https://doi.org/10.12688/wellcomeopenres.15389.1
 30 Sep 2019,  :123 (Latest published: 4
)https://doi.org/10.12688/wellcomeopenres.15389.2
v2
Page 1 of 12
Wellcome Open Research 2019, 4:123 Last updated: 02 OCT 2019
  Richard Kwizera ( )Corresponding author: kwizerarichard@ymail.com




: Data Curation, Investigation, Methodology, Writing – Review & Editing;  : Data Curation, Formal Analysis, Methodology,Kagimu E Bangdiwala AS
Validation, Writing – Review & Editing;  : Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing; Williams DA














The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 © 2019 Kwizera R  . This is an open access article distributed under the terms of the  , whichCopyright: et al Creative Commons Attribution License
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Kwizera R, Cresswell FV, Mugumya G   How to cite this article: et al. Performance of Lipoarabinomannan Assay using Cerebrospinal fluid
 Wellcome Open Research 2019, for the diagnosis of Tuberculous meningitis among HIV patients [version 2; peer review: 2 approved] 4
:123 ( )https://doi.org/10.12688/wellcomeopenres.15389.2
 19 Aug 2019,  :123 ( ) First published: 4 https://doi.org/10.12688/wellcomeopenres.15389.1
Page 2 of 12
Wellcome Open Research 2019, 4:123 Last updated: 02 OCT 2019
Introduction
In many human immunodeficiency virus (HIV) endemic 
countries, tuberculous meningitis (TBM) is the second most 
common cause of adult meningitis after cryptococcal meningitis1, 
and accounts for 1–5% of all tuberculosis (TB) cases2. TBM is 
the most severe form of TB and causes substantial morbidity 
and mortality in children and immunocompromised adults3,4. 
HIV infection is known to increase the risk of death in 
patients with TBM, as does TBM stage at the time of treatment 
initiation2,5. As is the case in cryptococcosis, high-quality nursing 
care is a critical component in managing TBM patients6.
Similarly, diagnosis of TBM is very challenging, especially in 
resource-limited settings where diagnosis relies on a combina-
tion of clinical, radiological and laboratory findings. The World 
Health Organisation (WHO) recommends Xpert MTB/RIF 
Ultra for the diagnosis of TBM using cerebrospinal fluid (CSF). 
Culture has many limitations related to turnaround time and 
sensitivity, and also requires considerable infrastructure and 
costs7. Therefore, the development of early point of care 
diagnosis for TBM is a priority. Recent studies have 
demonstrated that the next generation Xpert MTB/RIF Ultra 
is the most sensitive diagnostic test in HIV-positive adults7. 
However, Xpert MTB/RIF Ultra is not a bedside test, and thus 
access to same day results remain a challenge in many settings7.
Assays based on the detection of mycobacterial lipoarabinoman-
nan (TB-LAM) antigen in urine have emerged as potential 
point-of-care tests for extra-pulmonary TB8. There is evidence 
that urine TB-LAM may help to reduce mortality and predict 
poor outcomes9,10. The WHO recently added the TB-LAM assay 
onto its essential diagnostic list and recommended TB-LAM 
in hospitalised HIV positive adults with signs and symptoms 
of TB11,12. However, there are conflicting results about TB-LAM 
assay sensitivity for TBM diagnosis13 in CSF. With reference 
to definite TBM, Cox et al. found a 75% sensitivity using CSF 
from the fourth ventricle in an autopsy cohort from 91 
HIV-infected adults14. However, Bahr et al. had no positive 
TB-LAM tests using lumbar CSF from 67 HIV patients with 
meningitis13. In light of these results, and now that Xpert 
MTB/RIF Ultra is used instead of Xpert MTB/RIF, we aimed to 
further explore the utility of CSF TB-LAM test for the diagnosis 
of TBM among HIV-positive adults presenting with suspected 
meningitis.
Methods
Study setting and participants
Between April 2018 and June 2019, we assessed and performed 
diagnostic lumbar punctures on HIV-positive patients admitted 
to Mulago National Referral Hospital with suspected meningitis 
in Kampala, Uganda. Screening for TBM was performed 
cross-sectionally as part of the High Dose Rifampicin for 
Tuberculous Meningitis (RIFT) trial (ISRCTN registration 
number ISRCTN42218549, last updated 24/04/2018)15. 
Therefore, we did not calculate a sample size for the 
current study but included all participants that fit the screening 
criteria for the RIFT trial15. All included participants were 
HIV-infected adults (≥18 years old) who provided written 
informed consent by participant or surrogate, with a suspected 
diagnosis of TBM (meningitis symptoms, clinical signs of 
meningism). Demographic information and baseline characteris-
tics for participants were collected through clinical reviews using 
customized meningitis screening case report forms approved 
by the relevant ethics committees (Mulago Hospital Research 
Ethics Committee, Uganda National Council of Science and 
Technology, and the University of Minnesota). Opening 
pressures for CSF were measured using a manometer, followed 
by standard microbiology analysis (CrAg, cell count, protein, 
glucose, lactate, culture).
Diagnostic tests
In addition to standard microbiology analysis, CSF was tested 
with TB-LAM (Alere, Massachusetts, USA), and the test strip 
interpreted as per manufacturer’s instructions. Briefly, the 
protective foil cover was removed from each test and the strip 
labelled with the participant’s number. Two drops (or 60μL) of 
CSF were added to the sample pad. The test was then read after 
25 minutes under standard indoor lighting conditions. The 
reference card was used in interpretation of the results by 
holding it alongside the patient window. For positive results, 
purple/gray bars appeared in both the control window and the 
patient window of the strip. For negative results, one purple/
gray bar appeared in the control window of the strip and no bar 
appeared in the patient window of the strip. If there was no bar 
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in the control window of the strip, the result was considered 
invalid and the test repeated. The strips were retained and 
cross checked by a second researcher to corroborate the 
finding.
CSF was also tested with Xpert MTB/Rif Ultra (Cepheid). 
Briefly, 2ml of sample reagent was added to 1ml of whole CSF 
and then left to stand at room temperature for 15 minutes. 
Then, 2ml of the sample mixture was transferred into the Xpert 
MTB/Rif Ultra cartridge and loaded into the Xpert machine. 
The test was run for 90 minutes and results from the assay 
indicate whether or not Mycobacteria TB (MTB) was detected 
in the sample. If MTB was detected, the results also stated 
whether resistance to rifampin was detected.
Test analysis
Data were analyzed using STATA version 14 (STATA, College 
Station, Texas). The disease prevalence, sensitivity, specificity, 
positive predictive values, negative predictive values and test 
accuracy were estimated at 95% confidence interval (CI). The 
diagnostic performance of CSF TB-LAM was compared to 
positive CSF Xpert MTB/Rif Ultra (definite TBM) and a 
composite reference of probable or definite TBM according 
to the uniform case definition16. Summaries were made in 
frequency & percentages for each baseline characteristic con-
sidered as a categorical, and medians (interquartile range) when 
each characteristic is considered as a continuous variable. For 
baseline variables with some missing data, we calculated the 
statistics using the available numbers.
Ethical statement
Institutional review board approvals for the study and the 
associated screening process were obtained locally in Uganda 
(Mulago Hospital Research Ethics Committee, approval number 
MREC 1260); and from the London School of Hygiene and 
Tropical Medicine, UK (14388), University of Minnesota 
(1304M31361) and by the Uganda National Council of Science 
and Technology (HS136ES). Written informed consent for 
participation in the study and data publication was obtained 
from all participants or from their surrogates (e.g. family 
member or guardian) where the patient had altered mental status 
and did not have the capacity to provide consent.
Results
Overall, 59 HIV-positive hospitalized participants with 
suspected meningitis underwent diagnostic lumbar punctures, of 
which 20% (12/59) had definite TBM, 9% (5/59) had probable 
TBM, 25% (15/59) had possible TBM, and 46% (27/59) 
had not-TBM17. Of those with not-TBM (n=27), 10 had 
cryptococcosis. Women comprised 50% of participants with an 
overall median age for all participants of 33 years (interquar-
tile range [IQR]: 28, 40). Only 29% of the participants were 
receiving antiretroviral therapy at diagnosis. Among partici-
pants reporting a headache (n=57), the median duration of 
headache was 14 days (IQR: 14, 24). The CSF opening 
pressures at baseline (n=45) had a median of 200 mmH2O 
(IQR: 120, 260). Overall, 55% (n=36) had an acellular CSF, 
whilst those with a CSF lymphocytic pleocytosis had a 
median CSF white blood cell of 160 cells/μL (IQR: 135, 268) 
(Table 1). Only about 10% of the participants had cerebral imag-
ing done as the CT scanner was dysfunctional for part of the 
study period. About twenty five percent of the patients had a 
positive TB-LAM while 20% had a positive urine MTB/Rif Ultra.
With respect to the reference standard of definite TBM 
(positive CSF Xpert TB/Rif Ultra), the CSF TB-LAM assay 
had a sensitivity of 33% (4/12), specificity of 96% (45/47), 
positive predictive value (PPV) of 67% (4/6), and negative 
predictive value (NPV) of 85% (45/53). When compared to a 
composite reference of definite/probable TBM, the TB-LAM 
assay had a sensitivity of 24% (4/17), specificity of 95% 
(40/42), PPV of 67% (4/6), NPV of 76% (40/53) (Table 2). 
There were two false positive tests with TB-LAM (3+ grade), 
without any CSF pleocytosis, normal protein, normal glucose, 
negative cryptococcal antigen, and normal CSF opening 
pressure. One patient was discharged alive without TB therapy. 
The second patient had a headache for 60 days at presentation, 
but they were lost to follow up (i.e. self-discharged) without 
an etiologic diagnosis. In-hospital mortality in CSF TB-LAM 
positive patients was 17% (1/6) compared to 0% (0/8) in those 
with definite TBM by Xpert MTB/Rif Ultra but negative 
LAM. About 17% of patients had unknown outcome. This 
was because the study population included patients screened 
for a clinical trial but only a minority were subsequently 
enrolled into the trial. We endeavoured to follow screen failures 
through to hospital discharge but this was not possible in all 
cases.
Conclusion
In conclusion, a rapid CSF point of care test for TBM is needed; 
however, this study demonstrated a poor diagnostic performance 
of the existing Alere TB-LAM on CSF among HIV-associated 
tuberculous meningitis. Our results corroborate the findings 
of a recent Zambian study which demonstrated 22% sensitiv-
ity for CSF LAM against a reference standard of TB culture18. 
While the relatively modest sample size is a limitation, a 
larger sample size is unlikely to fundamentally alter the find-
ings of sensitivity. One explanation could be that TB-LAM 
is likely not be found in sufficient quantities in lumbar CSF. 
TB culture was not used, which is also a limitation of the 
accuracy analysis. However, Xpert Ultra has a sensitivity 
that is greater than culture in our setting7. The novel Fujifilm 
SILVAMP TB-LAM (FujiLAM) assay has been shown to 
have higher sensitivity in urine than the Alere TB-LAM and 
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Sensitivity Specificity PPV NPV Test Accuracy
Definite/probable 
TBM
28.8% (17/59) 23.5% (4/17) 95.2% (40/42) 66.7% (4/6) 75.5% (40/53) 74.6% (44/59)
95% CI 17.8 to 42.1% 6.8 to 49.9% 83.8 to 99.4% 28.7 to 90.8% 70.1 to 80.2% 61.6 to 85%
Definite TBM 20.3% (12/59) 33.3% (4/12) 95.7% (45/47) 66.7% (4/6) 84.9% (45/53) 83.1% (49/59)
95% CI 10.9 to 32.8% 9.9 to 65.1% 85.5 to 99.5% 29.3 to 90.6% 78.9 to 89.4% 71 to 91.6%
Data presented are the percentage, numerator/denominator, and 95% confidence intervals (CI). Test Accuracy = overall probability 
that a patient will be correctly classified. PPV = Positive predictive value, NPV = negative predictive value, TBM = tuberculous 
meningitis.
Table 1. Characteristics of the study population.
Baseline characteristics Overall (N=59) Definite TBM (n=12) Probable TBM (n=5) Possible TBM (n=15) Not-TBM (n=27)
N* Statistic N* Statistic N* Statistic N* Statistic N* Statistic
Women, n (%) 58 29 (50) 12 6 (50) 5 3 (60) 15 4 (26.7) 26 16 (61.5)
Age in years, median (IQR) 58 33 (28-40) 12 29 (28-33) 5 26 (24-34) 15 35 (32-43) 26 34 (26-46)
On ART, n (%) 47 29 (62) 11 7 (63.6) 2 2 (100) 11 3 (27.3) 23 17 (73.9)
Headache, n (%) 57 46 (81) 12 10 (83.3) 5 4 (80) 14 12 (85.7) 26 20 (76.9)
Duration of headache, 
median (IQR) days
45 14 (14-24) 10 17.5 (14-30) 4 14 (10.5-17.5) 12 17.5 (14-31.5) 19 14 (7-30)
Glasgow Coma Scale score, 
mean (SD)
55 13 (2.6) 12 12.5 (2.9) 5 11.8 (2.4) 14 12.7 (2.9) 24 14.3 (2.1)
CSF CrAg positive, n (%) 58 10 (17) 12 0 (0) 5 0 (0) 15 0 (0) 26 10 (38.4)
CSF Opening Pressure, 
median (IQR) mmH2o
45 200 (120-260) 7 180 (70-240) 3 260 (95-400) 13 190 (120-270) 22 215 (120-260)




55 160 (135-268) 8 280 (162.5-575) 4 173 (130-237.5) 3 80 (35-160) 4 145 (87.5-210)
CSF protein, median (IQR) 
mg/dL
52 57 (28-141) 11 184 (107-316) 5 158 (147-215) 13 44 (35-72) 23 31 (22-61)
CSF glucose, median (IQR) 
mg/dL
32 65 (34-82) 7 44 (19.8-61) 3 90 (68-108) 8 86 (56.3-104) 14 61 (31-80)
CSF lactate, median (IQR) 
mmol/L
36 3.9 (2.2-9) 8 9.7 (8.2-11.2) 4 9.2 (6.3-11.1) 8 3.4 (2.3-8.1) 16 2.4 (1.9-3.8)
Duration of hospitalization, 
median (IQR) days

























Data presented are percentages (%), medians and interquartile ranges (IQR). N= number of participants with data for each parameter. * Participants with data 
available. ART = antiretroviral therapy, CSF = cerebrospinal fluid, WBC = white blood cells.
warrants evaluation for diagnosis of TB meningitis both in 
urine and CSF19.  
Data availability
Underlying data
Figshare: CSFLAM_data set revised.xlsx. https://doi.org/10.6084/
m9.figshare.9415853.v117
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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